Latest news

• AstraZeneca’s severe asthma treatment approved in EU for self-administration

  AstraZeneca’s Tezspire (tezepelumab) has been approved for self-administration in patients with severe asthma aged 12 years and older after it received a positive opinion from the European Medicine

• AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

  Tezspire demonstrated reduced annualised rate of asthma exacerbations. AstraZeneca’s (AZ) Tezspire (tezepelumab) has been granted marketing authorisation in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) for

• AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

  AstraZeneca’s (AZ) Tezspire (tezepelumab) has been approved by the European Commission (EC) for use as an add-on maintenance treatment in patients 12 years and older with severe asthma, the

• AstraZeneca’s Tezspire recommended for approval in the EU by CHMP

  AstraZeneca (AZ) has received a recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the EU approval of Tezspire (tezepelumab) as an

• Tezspire approved in US for severe asthma

  After being granted a Priority Review in July 2021, AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) has been approved by the US Food and Drug Administration (FDA) as an add-on